Davis Polk advised the representatives of the underwriters in connection with the SEC-registered offering of 24,640,000 shares of common stock of Melinta Therapeutics, Inc., including 2,640,000 shares of common stock sold pursuant to the full exercise of the underwriters’ option to purchase additional shares. The offering resulted in $123.2 million of proceeds to Melinta Therapeutics, Inc., before deducting underwriting discounts and estimated offering expenses. Melinta Therapeutics, Inc.’s common stock is listed on the NASDAQ Global Market under the symbol “MLNT.”

Melinta is a commercial-stage pharmaceutical company focused on discovering, developing and commercializing differentiated anti-infectives for the hospital and select non-hospital, or community, settings that address the need for effective treatments for infections due to resistant gram-negative and gram-positive bacteria.

The Davis Polk corporate team included partner Deanna L. Kirkpatrick and associates Christopher M. Bezeg, Jenny J. Choi, Young-Min Cho and Ben A. Sherwood. The tax team included partner Michael Mollerus and associate Joshua J. Micelotta. Partner Pritesh P. Shah and associate Paul S. Lee provided intellectual property and technology advice. Counsel Betty Moy Huber provided environmental advice. All members of the Davis Polk team are based in the New York office.

Copy link to share post